Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The problem

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Apr 15, 2021 4:50pm

89 Views

Post# 33005284

RE:RE:RE:RE:The problem

Interesting. It was always a takeover candidate given the backing from Carlyle and Hellman Friedman private equity shops. Was public only briefly (<2 years) yet has 18 ANALYSTS COVERING IT! Shows you how the PE/VC guys DEMAND coverage for their names and they get it. Both firms still have 2-3 guys on the Board from their firms.

I know THTX isn't a PE backed firm, but having some smart money guys on the Board is very valuable and they should learn that from seeing the value creation with PPD in a bried amount of time. Soleus and whomever else they brought on with the OO is the closest they will get to having those intros and favors pulled in. They need to hit while Soleus is still hot on them.